Document Detail

Ivermectin Residue Depletion in Food Producing Species and its Presence in Animal Foodstuffs With a View to Human Safety.
MedLine Citation:
PMID:  22039793     Owner:  NLM     Status:  Publisher    
From a human safety perspective, the administration of ivermectin to food producing animal species entails potential risks related to the presence of drug residues in edible tissues, milk, and other derived products. The European Medicines Agency has established the maximum residue limits for ivermectin in the European Union, with values of 100 µg∙kg-1 in fat and liver and 30 µg∙kg-1 in kidney for all mammalian food producing species, in order to ensure that the amount of ivermectin that can be found in animal foodstuff is below dangerous levels for the consumers. According to these values, withdrawal periods after subcutaneous injection were recently established in the European Union (2009), in 49 days for products containing ivermectin as a single active substance or in combination with closantel, and in 66 days when combined with clorsulon. The marker residue for ivermectin was found to be H2B1a, which is the major component of the parent compound. The tissue distribution of residues and the overall ratios of marker to total residues were generally similar in most species, and the highest concentrations of ivermectin residues were found in fat and liver with high levels also detected in injection site muscles. Ivermectin is not licensed for use in animals from which milk is produced for human consumption, however its extra-label use should be considered regarding human safety, due to its long persistence in milk and milk-derived products.
M Escribano; M I San Andrs; J J de Lucas; A Gonzlez-Canga
Related Documents :
12324843 - Determination of total tin in canned food using inductively coupled plasma atomic emiss...
24265833 - Food availability and animal space use both determine cache density of eurasian red squ...
6564903 - Leuckart-specific impurities in amphetamine and methamphetamine seized in norway.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-31
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  -     ISSN:  1873-4316     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-11-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Departamento de Toxicologa y Farmacologa, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of MDR1 mutant dogs with macrocyclic lactones.
Next Document:  Acute Human Toxicity of Macrocyclic Lactones.